Skip to main content

Table 2 CYP3A4 and CYP3A5 genotypes in digestive cancer patients and healthy control individuals.

From: Genetic variability in CYP3A4 and CYP3A5in primary liver, gastric and colorectal cancer patients

CYP3A4

CYP3A5

Liver cancer

N (Frequency; 95% C.I.)

Stomach cancer

N (Frequency; 95% C.I.)

Colorectal cancer

N (Frequency; 95% C.I.)

Control subjects

N (Frequency; 95% C.I.)

*1A/*1A

*3/*3

144 (80.9; 75.1–86.7)

74 (90.2; 83.8–96.7)

121 (80.1; 73.8–86.5)

134 (82.2; 76.4–88.1)

*1A/*1A

*1/*3

17 (9.6; 5.2–13.9)

2 (2.4; 0–5.8)

18 (11.9; 6.8–17.1)

14 (8.6; 4.3–12.9)

*1A/*1A

*1/*1

0

0

0

1 (0.6; 0–1.8)

*1A/*1B

*3/*3

5 (2.8; 0.4–5.2)

1 (1.2; 0–3.6)

5 (3.3; 0.5–6.2)

1 (0.6; 0–1.8)

*1A/*1B

*1/*3

12 (6.7; 3.1–10.4)

5 (6.1; 0.9–11.3)

6 (4.0; 0.9–7.1)

12 (7.4; 3.3–11.4)

*1A/*1B

*1/*1

0

0

0

1 (0.6; 0–1.8)

*1B/*1B

*1/*3

0

0

1 (0.7; 0–2.0)

0